Recent topics in the management of herpes zoster.
amenamevir
herpes zoster
subunit vaccine
varicella vaccine
varicella-zoster virus
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
revised:
11
11
2022
received:
06
10
2022
accepted:
17
11
2022
pubmed:
22
12
2022
medline:
22
2
2023
entrez:
21
12
2022
Statut:
ppublish
Résumé
Herpes zoster is a disease caused by reactivation of the varicella-zoster virus that has been latently infecting the body and is more common among the elderly. In Japan, the incidence of herpes zoster has been increasing steadily and is expected to increase further in the future. In 2016, the varicella vaccine was expanded to include prevention of herpes zoster, and a new subunit vaccine was also launched in 2020. In recent years, anti-herpesvirus drugs with novel pharmacological effects have also been introduced, and the environment surrounding the treatment of herpes zoster is entering a new era.
Identifiants
pubmed: 36539935
doi: 10.1111/1346-8138.16666
doi:
Substances chimiques
Chickenpox Vaccine
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
305-310Subventions
Organisme : BIKEN Foundation
Organisme : Grants-in-Aid for Scientific Research from the Japanese Ministry of Health, Labour and Welfare for Research on Publicly Essential Drugs and Medical Devices (fiscal year 2008-2010)
ID : KHC1102
Organisme : Public-private Sector Joint Research on Publicly Essential Drugs (fiscal year 2011-2012)
ID : KHC1102
Informations de copyright
© 2022 Japanese Dermatological Association.
Références
Okuno Y, Takao Y, Miyazaki Y, Ohnishi F, Okeda M, Yano S, et al. Assessment of skin test with varicella-zoster virus antigen for predicting the risk of herpes zoster. Epidemiol Infect. 2013;141:706-13.
Toyama N. Invasive meningococcal infection, April 2013-October 2017, Japan. IASR. 2018;39:139-41.
Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med. 1965;58:9-20.
Thomas SL, Wheeler JG, Hall AJ. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet. 2002;360:678-82.
Toyama N, Shiraki K. Epidemiology of herpes zoster and its relationship to varicella in Japan: a 10-year survey of 48,388 herpes zoster cases in Miyazaki prefecture. J Med Virol. 2009;81:2053-8.
Toyama N, Shiraki K. Universal varicella vaccination reduced the incidence of herpes zoster in the child-rearing generation as its short-term effect. J Dermatol Sci. 2018;92:89-96.
Berger R, Florent G, Just M. Decrease of the lymphoproliferative response to varicella-zoster virus antigen in the aged. Infect Immun. 1981;32:24-7.
Burke BL, Steele RW, Beard OW, Wood JS, Cain TD, Marmer DJ. Immune responses to varicella-zoster in the aged. Arch Intern Med. 1982;142:291-3.
Takao Y, Miyazaki Y, Onishi F, Kumihashi H, Gomi Y, Ishikawa T, et al. The Shozu herpes zoster (SHEZ) study: rationale, design, and description of a prospective cohort study. J Epidemiol. 2012;22:167-74.
Tang H, Moriishi E, Okamoto S, Okuno Y, Iso H, Asada H, et al. A community-based survey of varicella-zoster virus-specific immune responses in the elderly. J Clin Virol. 2012;55:46-50.
Asada H, Nagayama K, Okazaki A, Mori Y, Okuno Y, Takao Y, et al. An inverse correlation of VZV skin-test reaction, but not antibody, with severity of herpes zoster skin symptoms and zoster-associated pain. J Dermatol Sci. 2013;69:243-9.
Okuno Y, Onishi F, Miyazaki Y, Okeda M, Yano S, Takao Y, et al. The Shozu herpes zoster (SHEZ) study: assessment of skin test with varicella skin test antigen ‘BIKEN’ for predicting the risk of herpes zoster and post-herpetic neuralgia. Community based prospective cohort study. J Clin Therap Med. 2014;30:905-15.
Imoto K, Okazaki A, Onishi F, Miyazaki Y, Okeda M, Yano S, et al. VZV skin-test reaction, but not antibody, is an important predictive factor for postherpetic neuralgia. J Dermatol Sci. 2015;79:235-40.
Nakamura Y, Miyagawa F, Okazaki A, Okuno Y, Mori Y, Iso H, et al. Clinical and immunologic features of recurrent herpes zoster (HZ). J Am Acad Dermatol. 2016;75:950-6.
Asada H. VZV-specific cell-mediated immunity, but not humoral immunity, correlates inversely with the incidence of herpes zoster and the severity of skin symptoms and zoster-associated pain: the SHEZ study. Vaccine. 2019;37:6776-81.
Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet. 1974;2:1288-90.
Takahashi M, Okada S, Miyagawa H, Amo K, Yoshikawa K, Asada H, et al. Enhancement of immunity against VZV by giving live varicella vaccine to the elderly assessed by VZV skin test. Vaccine. 2003;21:3845-53.
Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271-84.
Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372:2087-96.
Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Díez-Domingo J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375:1019-32.